BIOMAT Database Logo BIOMAT Database Logo

Phase II study of the combination of carmustine and 6-thioguanine in advanced malignant melanoma. 1987

R F Morton, and E T Creagan, and M H Veeder, and D L Elson, and J A Laurie, and R A Nelimark, and M N Chang

UI MeSH Term Description Entries
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D002330 Carmustine A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed) BCNU,1,3-Bis(2-Chloroethyl)-1-Nitrosourea,BiCNU,FIVB,N,N'-Bis(2-Chloroethyl)-N-Nitrosourea,Nitrumon
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

R F Morton, and E T Creagan, and M H Veeder, and D L Elson, and J A Laurie, and R A Nelimark, and M N Chang
Phase II study of mitolactol and semustine combination chemotherapy for advanced malignant melanoma.
June 1982, Cancer treatment reports,
R F Morton, and E T Creagan, and M H Veeder, and D L Elson, and J A Laurie, and R A Nelimark, and M N Chang
Phase II study of the combination of vinblastine, bleomycin, and cisplatin in advanced malignant melanoma.
March 1982, Cancer treatment reports,
R F Morton, and E T Creagan, and M H Veeder, and D L Elson, and J A Laurie, and R A Nelimark, and M N Chang
Dacarbazine, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma: a phase II study.
November 1987, Cancer treatment reports,
R F Morton, and E T Creagan, and M H Veeder, and D L Elson, and J A Laurie, and R A Nelimark, and M N Chang
Cisplatin and vindesine combination chemotherapy in advanced malignant melanoma: an EORTC phase II study.
December 1982, European journal of cancer & clinical oncology,
R F Morton, and E T Creagan, and M H Veeder, and D L Elson, and J A Laurie, and R A Nelimark, and M N Chang
Phase II study of epirubicin in advanced malignant melanoma.
January 1984, Investigational new drugs,
R F Morton, and E T Creagan, and M H Veeder, and D L Elson, and J A Laurie, and R A Nelimark, and M N Chang
Phase II study of mitolactol in advanced malignant melanoma.
June 1985, Cancer treatment reports,
R F Morton, and E T Creagan, and M H Veeder, and D L Elson, and J A Laurie, and R A Nelimark, and M N Chang
Interferon in combination with vinblastine in advanced malignant melanoma. A phase I-II study.
October 1989, Cancer,
R F Morton, and E T Creagan, and M H Veeder, and D L Elson, and J A Laurie, and R A Nelimark, and M N Chang
Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma. A Phase II Study of the EORTC Malignant Melanoma Cooperative Group.
September 1988, Cancer,
R F Morton, and E T Creagan, and M H Veeder, and D L Elson, and J A Laurie, and R A Nelimark, and M N Chang
Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinoma.
August 1991, Investigational new drugs,
R F Morton, and E T Creagan, and M H Veeder, and D L Elson, and J A Laurie, and R A Nelimark, and M N Chang
Prednimustine in advanced malignant melanoma: a phase II study.
December 1987, Cancer treatment reports,
Copied contents to your clipboard!